Sperm DNA Fragmentation Testing: When and Why

You have had a normal-looking semen analysis but conception is not happening, or you have had a recurrent miscarriage, or your RE has just suggested adding a DFI test. You want to know what fragmentation actually measures, when the test changes a decision, what cutoffs the lab uses, and whether it is worth the out-of-pocket cost.

Sperm DNA fragmentation testing is not part of a routine first-line workup. The AUA/ASRM 2021 Guideline endorses it selectively for four scenarios: unexplained infertility, recurrent pregnancy loss, recurrent IUI or IVF failure, and varicocele evaluation.^{1 3 5} The result is treated as a modifier of the treatment plan, not as a stand-alone diagnosis. Used in those settings, the test answers a question that the standard semen analysis cannot reach. Used outside them, it is more likely to confuse than to clarify.

What sperm DNA fragmentation actually measures

Sperm DNA fragmentation refers to single- and double-strand breaks in the DNA carried inside the sperm head. A standard semen analysis evaluates the outside of the sperm (concentration, motility, morphology, vitality) and tells you nothing about DNA integrity. A sperm cell can look entirely normal under the microscope and still carry damaged DNA.^{3 5}

Fragmentation arises from several mechanisms. Oxidative stress is the most-studied: reactive oxygen species, often elevated in varicocele, infection, smoking, obesity, and advanced paternal age, damage DNA strands inside the maturing sperm. Abnormal chromatin packaging during spermatogenesis leaves DNA more vulnerable to damage. Environmental exposures including heat, chemotherapy, and certain industrial chemicals contribute. Abortive apoptosis, where the apoptotic process starts but does not complete, leaves DNA damaged in cells that still mature and are ejaculated.

Sperm has minimal repair capacity after spermiogenesis. Once the damage is there, the oocyte has to do the repair work after fertilisation. Younger oocytes do this better than older ones, which is part of why the clinical relevance of fragmentation varies with the female partner's age.

When the test is appropriate per AUA/ASRM 2021

The current AUA/ASRM Guideline endorses sperm DNA fragmentation testing in selected settings rather than as routine.¹ The endorsed indications are:

• Unexplained infertility: the female workup is normal and the standard semen analysis is normal, and conception is not happening after an appropriate trial.
• Recurrent pregnancy loss: two or more clinical pregnancy losses, with the female workup completed and other contributors addressed.
• Recurrent IUI or IVF failure: the cycle did not produce expected fertilisation or implantation.
• Clinical varicocele under consideration for repair: the result helps weight the decision for surgical correction.
• Selectively in couples with advanced paternal age (commonly 40 years or older) or significant lifestyle exposures.

The guideline is explicit that DNA fragmentation testing is not recommended as a routine first-line test for every couple presenting with infertility.

When the test is not yet useful

There are situations where adding fragmentation testing too early adds cost without changing the plan.

If the first semen analysis is abnormal, the right next step is usually to characterise the abnormality on a second analysis, address what is visible (lifestyle, varicocele evaluation, hormone panel), and only consider fragmentation if the treatment response is poor. Running the test before fixing what is visible muddles the interpretation.

Routine pre-IUI workup in a couple with no prior failure does not need fragmentation testing. The workup of azoospermia uses a different pathway entirely; fragmentation is not the question being asked. And the search for a "fertility score" is misplaced here. DFI is a number, but it is not a single predictor of outcome; the same DFI value carries different weight depending on the clinical context.

The assays, and why the cutoffs differ

Four assays are commonly used, and they do not give interchangeable results. The cutoffs are lab-specific. Your number means what your lab's cutoffs say it means.

SCSA (sperm chromatin structure assay) uses flow cytometry to identify sperm with denaturable DNA after acid exposure. The result is reported as a DNA Fragmentation Index (DFI percent). A commonly cited threshold framework is DFI ≤ 15 percent as normal, 15 to 30 percent as moderate, and above 30 percent as high, though individual lab reference ranges may differ.⁵

TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) directly labels DNA strand breaks with a fluorescent marker. Thresholds vary widely between labs depending on staining protocol and scoring method.

Comet assay uses single-cell gel electrophoresis to detect DNA fragmentation in individual sperm. It is sensitive but heavily lab-dependent.

SCD or Halo assay (sperm chromatin dispersion) is a manual scoring method, widely available and lower cost, but with more inter-observer variability.

Compare your number to your specific lab's reference range, not to a universal cutoff you read in a journal abstract. A DFI of 25 percent may be flagged as elevated at one lab and as borderline at another.

What an elevated DFI changes about the plan

The clinical use of an elevated DFI is to shift the treatment decision in a specific direction. In recurrent miscarriage with a normal female workup, an elevated DFI prompts a discussion about an antioxidant trial, lifestyle intervention, and a re-test in 3 months before further ART decisions.^{4 5} In unexplained infertility with markedly elevated DFI, some evidence supports moving past IUI directly to IVF or ICSI rather than burning IUI cycles.³

In IVF failure with high DFI, testicular sperm extraction (TESE) for ICSI has shown improved outcomes in selected cases, on the basis that testicular sperm typically have lower DNA damage than ejaculated sperm.^{3 5} In clinical varicocele with high DFI, the case for surgical varicocele repair is more strongly supported.

The pattern in each scenario is the same: the DFI does not stand alone; it sits inside a clinical question and helps weight the answer.

Interventions with the strongest evidence

When DFI is elevated and the clinical scenario fits, the interventions with the best evidence are:

1. Lifestyle: smoking cessation, alcohol reduction, heat avoidance, weight optimisation where applicable.
2. Time: spermatogenesis is approximately 74 days plus around 14 days of epididymal transit. Re-test no sooner than 3 months after any change.
3. Varicocele repair when clinically indicated. Meta-analytic data show DFI improvement after repair.
4. Antioxidant supplementation (combinations including zinc, selenium, and vitamin E, vitamin C, CoQ10, carnitine, and folate). The Cochrane 2019 review found low- to moderate-quality evidence of improved pregnancy and live birth rates with antioxidant use in male subfertility, with a modest effect size and significant heterogeneity in the trials.⁴ This is worth saying honestly: the evidence supports a trial, not a guarantee.
5. Treatment of infections and leukocytospermia where present.

The detailed approach to the 3-month preconception window is in the sperm 74-day supplement and lifestyle window once that post is up.

What does not help

Some things to actively avoid:

• At-home DFI kits that are not validated against clinical assays. The technology to measure DNA fragmentation reliably is not the same as the technology that fits in a consumer kit.
• Re-testing every cycle hoping for a different number. Spermatogenesis takes 3 months; re-tests at shorter intervals do not capture an intervention's effect and add cost without information.
• Starting testosterone to "boost sperm." Exogenous testosterone suppresses pituitary signalling and suppresses spermatogenesis. It is the opposite of what is needed.
• Generic male fertility supplement blends with under-dosed components and proprietary blends that do not disclose individual quantities. The Cochrane evidence is for specific doses of specific antioxidants in trial settings, not for whatever combination ends up in a marketing-driven blend.

Cost, timing, and where to get it done

Sperm DNA fragmentation testing is typically not covered by insurance and varies in cost. Out-of-pocket figures in the UK commonly fall in the £150 to £400 range; in the US, $200 to $600 is typical, depending on assay and lab. Some IVF clinics offer the test as an add-on to a fresh cycle; specialist andrology labs run it as a stand-alone.

Sample requirements mirror a standard semen analysis: 2 to 7 days of abstinence, collection in a sterile container at the lab where possible, and timely analysis. If a lifestyle intervention is being trialled, the re-test sits at least 3 months out to allow the spermatogenesis cycle to reflect the change.

What to ask your RE or urologist

Five questions that move the decision forward.

1. "Does our clinical situation (unexplained infertility, recurrent loss, failed cycle, varicocele under evaluation) fit the AUA/ASRM indications for this test?"
2. "Which assay does the lab use, and what are their specific reference cutoffs?"
3. "If the result is high, what specifically would change in our treatment plan?"
4. "Should varicocele evaluation be done first?"
5. "When would the re-test sit, and what interventions are you recommending in between?"

A clinician who orders the test thoughtfully will have a clear answer for each of these.

What's next

• For the workup as a whole and where this test fits: the male fertility workup overview
• For the parameter-by-parameter read of the standard analysis: how to read a semen analysis
• For the WHO 2021 reference ranges and what borderline means on the standard analysis: normal sperm count ranges
• For the 3-month lifestyle window before re-testing: preparing your body
• For the partner-side recurrent loss workup: recurrent loss workup tests
• If considering moving past IUI after a failed cycle: the IUI and IVF section hubs

Sources

1. Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg ML, Lamb DJ, et al. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part I and II. Fertility and Sterility 2021;115(1):54-69. https://doi.org/10.1016/j.fertnstert.2020.11.015
2. Practice Committee of the American Society for Reproductive Medicine. The clinical utility of sperm DNA integrity testing: a guideline. Fertility and Sterility 2013;99(3):673-677. https://doi.org/10.1016/j.fertnstert.2012.12.049
3. Esteves SC, Zini A, Coward RM, Evenson DP, Gosálvez J, Lewis SEM, et al. Sperm DNA fragmentation testing: Summary evidence and clinical practice recommendations. Andrologia 2021;53(2):e13874. https://doi.org/10.1111/and.13874
4. Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database of Systematic Reviews 2019;3(3):CD007411. https://doi.org/10.1002/14651858.CD007411.pub4
5. Agarwal A, Majzoub A, Baskaran S, Panner Selvam MK, Cho CL, Henkel R, et al. Sperm DNA Fragmentation: A New Guideline for Clinicians. World Journal of Men's Health 2020;38(4):412-471. https://doi.org/10.5534/wjmh.200128